News

Contract Pharma
contractpharma.com > breaking-news > astrazenecas-enhertu-gets-priority-review-from-fda-for-her2-positive-breast-cancer

AstraZeneca’s Enhertu Gets Priority Review from FDA for HER2-Positive Breast Cancer

21+ hour, 50+ min ago  (267+ words) Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. The FDA granted the Priority Review for…...